Annual Business Review - Pt 2

AstraZeneca PLC
3 December 2001

TWO OF TWO



                        AstraZeneca R&D Pipeline: NCEs
                               3 December 2001



Cardiovascular


  Compound             Mechanism               Indication     Phase  Estimated
                                                                      Filing
                                                                     MAA   NDA
Crestor        Statin                      Hyperlipidemia      DFL  Filed Filed
Exanta(TM)     Thrombin inhibitor (s.c)    Prevention of VTE   DFL   3Q   >2004
(melagatran)                                                        2002
Exanta(TM)(H376 Thrombin inhibitor         Prevention of VTE   DFL   3Q    2Q
/95)                                                                2002  2003
Exanta(TM)(H376 Thrombin inhibitor         Prevention of       DFL   2Q    2Q
/95)                                       stroke in AF             2003  2003
Exanta(TM)(H376 Thrombin inhibitor         Treatment of VTE    DFL   1H   2004
/95)                                                                2003
Exanta(TM)(H376 Thrombin inhibitor         Post Acute          CT   >2004 >2004
/95)                                       Coronary Syndrome
AZD 6140      P2T antagonist               Arterial            CT   >2004 >2004
                                           thrombosis
AZ 242        PPAR agonist                 Diabetes /Insulin   CT   >2004 >2004
                                           resistance
AZD 7545      PDK inhibitor                Diabetes            CT   >2004 >2004
              (anti-diabetic)
AZD 7009      Atrial Repolarisation        Atrial              CT   >2004 >2004
              Delaying Agent (ARDA)        Fibrillation





Gastrointestinal


 AR-H047108   Reversible acid pump inhibitor    Acid related GI    CT  >    >
                                                disease               2004 2004
AZD 3355      Inhibitor of transient lower      Gastroesophageal   CT  >    >
(Reflux       esophageal sphincter relaxations  reflux disease        2004 2004
inhibitor)    (TLESR )                          (GERD)
Rofleponide   Oral steroid with topical action  Inflammatory bowel CT  >    >
                                                disease               2004 2004



CNS


NXY-059  Free radical trapping agent           Stroke           CT  >2004 >2004
NAD 299  5HT1A antagonist                      Anxiety/         CT  >2004 >2004
                                               Depression
AR-A2    5HT1symbol 98 /f 'Symbol' /s 12b      Anxiety/         CT  >2004 >2004
         antagonist                            Depression
ZD 0947  K+ channel opener                     overactive       CT  >2004 >2004
                                               bladder
AZD 5106 NK-2 antagonist                       overactive       CT  >2004 >2004
                                               bladder





Oncology


Compound Mechanism                           Indication        Phase Estimated
                                                                       Filing
                                                                     MAA   NDA
Faslodex Estrogen Receptor Down regulator    2nd line Advanced  DFL       Filed
TM                                           breast cancer           2002
Faslodex Estrogen Receptor Down regulator    1st line Advanced  DFL        2002
TM                                           breast cancer           2002
IressaTM Signal transduction inhibitor       NSCLC and other    DFL   2Q   4Q
         (Epidermal growth factor receptor   solid tumours           2002 2001*
         tyrosine kinase inhibitor)                                   *
ZD 9331  Thymidilate synthase inhibitor (iv) Solid tumours      CT   2004 2004
ZD 9331  Thymidilate synthase inhibitor      Solid tumours      CT    >   >2004
         (oral)                                                      2004
ZD 6126  Vascular targeting agent            Solid tumours      CT    >   >2004
                                                                     2004
AZD 6474 Angiogenesis inhibitor (Vascular    Solid tumours      CT    >   >2004
         endothelial cell growth factor                              2004
         receptor tyrosine kinase inhibitor)
AZD 2171 Angiogenesis inhibitor (Vascular    Solid tumours and  CT    >   >2004
         endothelial cell growth factor      haematological          2004
         receptor tyrosine kinase inhibitor) malignancies
AZD 3409 Farnesyl-transferase inhibitor      Solid tumours      CT    >   >2004
                                                                     2004
         ( FAR )

*US filing NSCLC monotherapy 4Q 2001, combination 2Q 2002; EU filing NSCLC
monotherapy and combination 2Q 2002



Respiratory and Inflammation


Rofleponide        Intranasal steroid         Rhinitis          CT  2004  2004
palmitate
ZD 4407            5-lipoxygenase inhibitor   COPD              CT  >2004 >2004
ZD 2315            Immuno modulator           Rheumatoid        CT  >2004 >2004
                                              Arthritis
AZD 9056           P2X7 receptor antagonist   Rheumatoid        CT  >2004 >2004
                                              Arthritis
AZD 8309            Chemokine receptor        Rheumatoid        CT  >2004 >2004
                   antagonist                 Arthritis





Pain Control


AZD 3582             Nitric oxide NSAID        Acute /chronic    CT >2004 >2004
(NO-naproxen)        derivative                pain
AZD 4282 (oral       NMDA Antagonist           Neuropathic pain  CT >2004 >2004
glycine)



Infection


AZD2563 Oxazolidinone     Gram positive infections, including      CT  >    >
        antibiotic        multi-resistant strains                     2004 2004











AstraZeneca R&D Pipeline: Line Extensions



Cardiovascular


 Compound         Mechanism              Indication      Phase     Estimated
                                                                    Filing
                                                                  MAA     NDA
Atacand(R) Angiotensin II           Hypertension          DFL   3Q 2002 3Q 2002
           antagonist               outcomes
                                    (SCOPE study)
                                    CHF outcomes          DFL   2H 2003 2H 2003
                                    (CHARM study)
                                    Diabetic retinopathy  DFL    >2004   >2004

NB. Paediatric programmes ongoing/planned: Atacand(R), Seloken(R)/Toprol(R).



Gastrointestinal


Nexium(R)  Proton pump inhibitor  Multiple indications   DFL   2003*    2003*

*Multiple indications from 2003 onwards



CNS


Seroquel(R) D2/5HT2 antagonist         Granules          DFL  1H 2003  1H 2003
Seroquel(R) D2/5HT2 antagonist         Sustained release DFL  4Q 2002  4Q 2002
Seroquel(R) D2/5HT2 antagonist         Mania             DFL  1H 2003  2H 2002
Zomig(R)    5-HT1B/1D receptor agonist Adolescents       DFL  2H 2003  2H 2003
Zomig(R)    5-HT1B/1D receptor agonist Nasal spray       DFL   Filed   1Q 2002



Oncology


Arimidex(R)  Aromatase inhibitor Adjuvant Breast Cancer DFL   1Q 2002  1Q 2002
Casodex(R)   Anti-androgen       Early Prostate Cancer  DFL    Filed   4Q 2001
Zoladex(R)   LHRH agonist        Premenopausal          DFL  Launched  1H 2003

                                 Adjuvant Breast Cancer







Respiratory


Symbicort(R)      Inhaled steroid/long-acting COPD              DFL  1Q
Turbuhaler(R)     ss2 agonist                                       2002
Symbicort         Inhaled steroid/long-acting Single therapy    DFL  2H
Turbuhaler        b2 agonist                  for asthma            2003
Symbicort(R) pMDI Inhaled steroid/long-acting Asthma            DFL  2H   2004
                  ss2 agonist                                       2003

Oxis(R)           Long-acting b2 agonist      COPD              DFL  2Q
Turbuhalera*                                                        2002
Oxis(R)           Long-acting b2 agonist      Paediatrics       DFL Filed
Turbuhalera*                                  Asthma
Oxis(R) pMDI*     Long-acting b2 agonist      Asthma / COPD     DFL  2H
                                                                    2003

* Following a review, Oxisa will not be developed for the US market and
resources will focus on Symbicort(R) pMDI



Pain Control


 Compound         Mechanism            Indication      Phase  Estimated Filing
                                                                 MAA      NDA
Naropin(R)  Sodium channel blocker Spinal anaesthesia   DFL   Filed        *


* Naropin will not be filed for spinal anaesthesia in the US





Infection


 Compound      Mechanism             Indication         Phase Estimated Filing
                                                              MAA      NDA
Merrem   Carbapenem           Use in Neutropenics        DFL         2H 2003
(R)      antibiotic
Merrem   Carbapenem           Skin and soft tissue       DFL         1H 2003
(R)      antibiotic           infections







               AstraZeneca R&D Pipeline: Discontinued Compounds



Cardiovascular


  Compound                               Mechanism
 AR-H050642  Atrial Repolarisation Delaying Agent (ARDA) - replaced by AZD 7009
ZD 4927      Factor Xa inhibitor





Oncology


Compound                                    Mechanism

ZD 0473*           3rd generation platin (iv)
ZD 0473*           3rd generation platin (oral)

*Handed back to Anormed 26 Nov 2001



Respiratory and Inflammation


               Compound                                Mechanism
AZD 6942 (CCR2b)                        Immuno modulator





Comments



As disclosure of compound information is balanced by the business need to
maintain competitive advantage, some compound information has not been
disclosed at this time.



Previous pipeline tables have displayed projects in the pre-clinical stage
(prior to the selection of a candidate drug).  The current table shows
compounds in concept testing and development for launch only.



AstraZeneca is using a new terminology for the stage of development;



CT - concept testing, from CD nomination, through to phase I and phase II
completion

DFL - development for launch, phase IIIa and phase IIIb activities conducted
prior to filing



Other abbreviations;



CD - Candidate Drug

MAA - Marketing Authorisation Application (Europe)

NDA - New Drug Application (USA)







                                   - Ends -